Eloxx Pharmaceuticals, Inc.
ELOX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $23,727 | $45,569 | $14,590 | $26,349 |
| G&A Expenses | $10,692 | $20,449 | $14,847 | $24,206 |
| SG&A Expenses | $10,692 | $20,449 | $14,847 | $24,206 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $34,419 | $66,018 | $29,437 | $50,555 |
| Operating Income | -$34,419 | -$66,018 | -$33,455 | -$50,555 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1,646 | -$709 | -$1,122 | -$319 |
| Pre-Tax Income | -$36,065 | -$66,727 | -$34,577 | -$50,874 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36,065 | -$66,727 | -$34,577 | -$50,874 |
| % Margin | – | – | – | – |
| EPS | -16.65 | -38.15 | -34.47 | -53.46 |
| % Growth | 56.4% | -10.7% | 35.5% | – |
| EPS Diluted | -16.65 | -38.15 | -34.47 | -53.46 |
| Weighted Avg Shares Out | 2,166 | 1,749 | 1,003 | 952 |
| Weighted Avg Shares Out Dil | 2,166 | 1,749 | 1,003 | 952 |
| Supplemental Information | – | – | – | – |
| Interest Income | $274 | $8 | $337 | $1,072 |
| Interest Expense | $1,949 | $1,259 | $1,409 | $1,616 |
| Depreciation & Amortization | $695 | $960 | $571 | $559 |
| EBITDA | -$31,746 | -$64,508 | -$32,597 | -$48,699 |
| % Margin | – | – | – | – |